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Abstract
Over 3,000 human genes can be expressed from a single allele in one cell, and from the other 
allele – or both – in neighboring cells. Little is known about the consequences of this epigenetic 
phenomenon, monoallelic expression (MAE). We hypothesized that MAE increases expression 
variability, with potential impact on human disease. Here, we use a chromatin signature to infer 
MAE for genes in lymphoblastoid cell lines and human fetal brain tissue. We confirm that across 
clones, MAE status correlates with expression level, and that in human tissue datasets, MAE genes 
show increased expression variability. We then compare mono- and biallelic genes at three distinct 
scales. In the human population, we observe that genes with polymorphisms influencing 
expression variance are more likely to be MAE (P < 1.1 × 10−6). At the trans-species level, we 
find gene expression differences and directional selection between humans and chimpanzees more 
common among MAE genes (P < 0.05). Extending to human disease, we show that MAE genes 
are underrepresented in neurodevelopmental CNVs (P < 2.2×10−10) suggesting that pathogenic 
variants acting via expression level are less likely to involve MAE genes. Using neuropsychiatric 
SNP and SNV data, we see that genes with pathogenic expression-altering or loss-of-function 
variants are less likely MAE (P < 7.5×10−11) and genes with only missense or gain-of-function 
variants are more likely MAE (P < 1.4×10−6). Together, our results suggest that MAE genes 
tolerate a greater range of expression level than BAE genes and this information may be useful in 
prediction of pathogenicity.
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INTRODUCTION
In recent years, we and others have discovered that a large fraction of human genes (10 - 
30%) are subject to monoallelic expression in a tissue-dependent manner. The known 
biological properties of this epigenetic mechanism have been reviewed recently1, and the 
most relevant aspects are summarized in brief: 1) MAE is a cell-type specific property for 
each gene; the majority of MAE genes show variable patterns across cell-types with 
constitutive biallelic expression (BAE) in some cell types and MAE in others. 2) Allelic 
choice for each gene undergoing MAE is independent. Multiple genes are simultaneously 
subject to MAE in a given cell and its clonal progeny, and undergo independent choice at 
each locus. 3) MAE is highly mitotically stable over multiple cell divisions. 4) MAE status 
of genes strongly correlates with a specific gene-body chromatin signature; a polymorphism-
independent approach based on this (Monoallelic Gene Inference from Chromatin; MaGIC) 
can be used in complex samples to predict MAE status in tissues of interest2, 3.
MAE is known to generate otherwise similar cells with different functional properties based 
on allelic composition. For example, the MAE status of Tlr4 in a heterozygous NULL 
results in two distinct cellular populations with respect to LPS response4. However, sources 
of MAE-related cell-to-cell variation beyond functional allelic differences have remained 
relatively unexplored. It is rarely noted that while other types of monoallelic expression (e.g. 
olfactory allelic exclusion, imprinting, X-inactivation) involve obligatory choice of only one 
allele in any single cell or clone, a typical MAE gene can be expressed biallelically in some 
clonal lineages and monoallelically in others within the same tissue- or cell-type. In light of 
overall evidence of random clonal make-up of a given tissue5, this observation strongly 
suggests that different individuals will have different proportions of monoallelic- and 
biallelic-expressing cells for a specific MAE gene in a relevant tissue. The consequences of 
this epigenetic source of variation for cell-to-cell variability and individual variation are 
currently unknown.
Specifically, it has been shown that MAE genes in a monoallelic state have lower expression 
levels than in a biallelic state in the scenarios tested to date6. However, assessing the 
consequences of silencing one allele for overall gene expression levels in individual cells 
and in tissues across the population has been technically challenging due to methodological 
issues and small numbers of confirmed MAE genes. The relationship between monoallelic 
state and expression range in individual clones has not been tested in human cells beyond 
individual examples7, and other evidence remains equivocal, as one group has argued for 
possible cases of dosage compensation in mouse NPCs8.
Further, it is not known what effect expression variability across cells has on tissue-level 
expression variability. One possibility is that MAE is a mechanism for exerting tight control 
over expression level in a developing tissue by lowering expression level in a fraction of 
cells6. It has been previously proposed that a stochastic model with limiting amounts of 
transcription or chromatin factors could, by chance, generate a population with zero, one, or 
two active alleles consistent with MAE. This model carries the strong implication of tight 
control in overall expression level of MAE genes and would predict that expression 
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variability across individuals would be unlikely. However, it is not clear how this model 
applies to mitotically stable MAE.
We hypothesized that MAE is likely to increase expression level variability not only among 
cells in the same tissue but also among tissues in different individuals as a result of clonal 
composition. Based on previous observations5, we assume that clonal composition is subject 
to random developmental events in otherwise identical genotypes. Consequently, proportions 
of monoallelic and biallelic active cells for any given MAE gene are likely to differ across 
individuals. If monoallelic expression is lower than biallelic expression, individuals with 
increased proportions of monoallelic clonal lineages will exhibit lower expression level in 
the tissue overall than individuals with increased proportions of biallelic lineages.
Even small gene expression level differences are known to have a major impact on human 
variation and in evolution. For example, common DNA polymorphisms associated with 
expression level (eQTLs) have been shown to have major functional enrichment in genome-
wide association studies for a variety of complex heritable traits, and copy number variants 
which have a large impact on the expression of the genes within them are often pathogenic 
for neurodevelopmental disorders9-14. Similarly, recent data suggests that epigenetic and 
regulatory changes contribute disproportionately to evolutionary difference, particularly in 
the brain15-17. Therefore, if MAE impacts expression variance, it may have consequences for 
the function and evolution of MAE genes, and leave a specific signature on human variation 
and disease.
To assess the validity of our hypotheses, we first assessed expression differences in MAE 
genes with different allelic state (monoallelic or biallelic) in human clonal cell lines. We 
then used a previous catalog of MAE genes18 identified in lymphoblastoid cell lines (LCLs) 
using the MaGIC method, and generated a novel set of such genes in human fetal brain by 
the same method, in order to investigate the extent and consequences of MAE expression 
level variation in existing datasets. We examined human expression data to show that the 
variance of MAE genes is indeed higher than for BAE genes, and used genetic mapping of 
human expression variability data to show that MAE genes are more likely to have 
significant expression variability quantitative trait loci (evQTLs) than BAE genes.
To assess the long-term consequences of the MAE-induced expression variation, we 
analyzed data describing species expression level differences between humans and non-
human primates. Genes with MAE status have higher inter-species expression variance and 
are more likely to have acquired differences in expression level during evolution compared 
with genes classified as constitutive BAE. We also performed an analysis of pathogenic 
neurodevelopmental copy number variant (CNV) data in humans to show that MAE genes 
are represented in polymorphic CNVs in the population but specifically depleted in 
pathogenic CNVs, suggesting that they are genes for which a range of expression level is 
tolerated in humans. We support this disease-related hypothesis by analyzing common and 
rare variants associated with schizophrenia and autism, where we find that risk factors 
predicted to act on expression level underrepresent MAE genes and those predicted to act 
via potential gain-of-function are enriched for such genes. Thus, tissue-specific epigenetic 
characteristics of genes may be complementary to current information about mutational 
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impact and evolutionary conservation in future research and clinical prediction of genetic 
variant pathogenicity.
MATERIALS AND METHODS
Categorization of genes as MAE or BAE based on histone marks
Analysis was performed on a set of MAE and BAE genes compiled from a recently 
published newly-available genome-wide dataset2. Briefly, the dataset indicates the 
monoallelic or biallelic status of genes in six human cell types represented by seven cell 
lines, on the basis of an experimentally tested specific chromatin signature (co-occurrence of 
H3K27me3 silencing mark and H3K36me3 active mark on the gene body), and expression 
data. We selected the GM12878 (lymphoblast) cell line for our analysis of MAE in blood. To 
predict that a gene is MAE, we required classified MAE status with expression rank of 50% 
or more after quantile rank normalization of expression levels. In GM12878 this corresponds 
to RPKM ~1, or 5-10 transcripts per cell. The threshold was used to exclude any genes 
which are monoallelic only in non-physiologically relevant expression levels. To consider a 
gene BAE, we required expression rank of 50% and inferred BAE status. Thus, if a gene was 
inferred monoallelic only at low expression (rank < 50%), it was not included in the MAE 
set, nor was it considered to be positively BAE, and was therefore excluded from 
consideration. In addition, short genes (<2,500) were excluded from the analysis because the 
gene body chromatin signature signal was found to be less reliable for such genes3. To 
generate predictions for fetal brain, we used the ChIP-Seq dataset from Epigenome 
Roadmap19 which was analyzed according to the method previously described2. Briefly, 
H3K27me3 and H3K36me3 signal on the gene body was integrated and normalized to input 
signal. The resulting data was quantile-normalized and processed with a prediction model 
trained on an analogous dataset derived from human LCLs, for which the MAE and BAE 
gene status was experimentally verified7.
Experimental determination of expression level differences of MAE genes in monoallelic 
compared to biallelic clones
We analyzed a previously published dataset (GSE52090) of RNA-seq on two lymphoblastic 
clonal cell lines. Details on the derivation of clonal cell lines and the RNA-seq library 
preparation can be found in the original publication2. Briefly, the clonal cell lines were 
derived from the GM12878 cell line obtained from the Coriell depository through single-cell 
sorting, and polyA-selected libraries were prepared from Trizol-extracted RNA and 
sequenced on an Illumina HiSeq 2000. The RSEM package20 was used to compute expected 
read counts on hg19 with UCSC-derived gene models. The DESeq R-package (10.1186/
gb-2010-11-10-r106) was used to estimate size factors for each library and for variance 
stabilization to allow for cross-clonal comparison of expression levels for genes with at most 
two-fold difference in expression (the expected dosage difference between monoallelic and 
biallelic state of an MAE gene).
To compare expression levels of the MAE genes, we selected all genes which were 
determined to be monoallelically expressed in one clone, and biallelically expressed in the 
other as group 1 (different state), and all genes either monoallelically or biallelically 
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expressed in both clones as group 2 (consistent state). Further subgroups were examined 
according to specific state in each clone (monoallelic in clone DF1 and biallelic in DF2; 
monoallelic in clone DF2 and biallelic in DF1; consistent -- monoallelic in both; consistent 
-- biallelic in both). A gene was determined to be monoallelically expressed if the proportion 
of reads with one variant genotype exceeded 2/3 (>67%) and the P-value of the binomial test 
for bias was less than 0.05. Benjamini-Hochberg FDR correction was used to correct for 
multiple comparisons. Biallelic expression was determined by equivalence testing, as 
described elsewhere2. Briefly, an interval of equivalence is defined for bias of +/−17%, and 
genes with bias estimate which confidently falls within this interval are considered 
biallelically expressed.
Human expression variance dataset
Gene expression data from the GTEx consortium 21 was downloaded from the GTEx portal 
(http://www.gtexportal.org/, version V6p) and processed using YARN 22 (bioconductor.org/
packages/yarn). In total, we analyzed 393 whole blood samples, 118 EBL-transformed cell 
lines samples, and 108 frontal cortex samples. The full list of samples used is available in 
Table S1. We applied smooth quantile normalization 23 that normalizes samples in a tissue 
aware manner and returns a log-transformed normalized matrix. We filtered out genes with 
mean coverage across samples lower than 10 reads per gene and calculated the standard 
deviation as a gene-wise estimation of dispersion. To compare dispersions between genes 
with different levels of expression, we split genes into 5 interquartile bins according to the 
level of expression. We sampled 300 genes from each bin (if either of the MAE or BAE 
genes in the bin contained less than 300 genes, we sampled this amount of genes across this 
bin) and then applied Wilcoxon test to test for higher dispersion levels of MAE genes. The 
results of these calculation are available in Table S2.
evQTL Dataset
We utilized published data on human expression variance quantitative trait loci (evQTLs) in 
order to assess genetic regulation of expression variance24. In brief, the largest dataset used 
in this study was gene expression omnibus (GEO) dataset GSE6536, which contained 
measurement of LCL mRNA expression data from HapMap individuals from Illumina 
human whole-genome expression array (WG-6 version 1)25. These data included 16,992 
genes (19,440 probes). Genotype data were obtained from the HapMap project for 210 
unrelated CEU and YRI parent samples overlapping with the expression data. Genotype data 
were also extracted from the 1,000 genomes project (1KGP) for individuals overlapping 
with expression data. Regression models were used to identify significant SNP effects on 
variance P < 1 × 10−8 (equivalent to Bonferroni adjusted P < 0.01). For these putative 
significant loci, Ppermutation < 0.001 and F-K test P < 0.01 for homogeneity of variance were 
also required for the final set of 166 evQTLs from GSE6536 considered in our study. We 
also consulted the lists of eQTLs reported in the original manuscript to be sure they did not 
bias our analysis25.
Human and non-human primate expression dataset
In order to examine inter-species variability and evidence for natural selection, we utilized 
data from a previous study26. In brief, five each human, chimpanzee, and rhesus macaque 
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LCLs were used. Peptide expression was measured by stable isotope labeling by amino acids 
in cell culture (SILAC) using high-resolution quantitative mass spectrometry in order to 
compare protein expression levels. RNA-seq data was also collected from the same samples 
for comparisons of mRNA expression. Both mRNA and protein expression were measured 
in at least three individuals from all three species for 3,390 genes. For this set of genes, 
supplementary data was available including the results of a test of protein level species 
differences, mRNA level species differences, protein and mRNA variance, RPKM for 
mRNA measurements, and the best fitting selection model for both protein and mRNA: 1 = 
expression level pattern consistent with directional selection along human lineage, 2 = 
expression level pattern consistent with directional selection along chimpanzee lineage, 3 = 
undetermined pattern, 4 = patterns with no significant difference between mean expression 
levels; 5 = evidence for relaxation of constraint along human lineage, 6 = evidence of 
relaxation of constraint along chimpanzee lineage.
NDD CNV datasets
In order to test the hypothesis that genes in pathogenic copy number variants would be 
depleted for MAE genes, we used the datasets in Jeffries et al27 (Supplementary File_S1; 
refs. 28-35) and added several more recent datasets containing lists of pathogenic CNVs 
implicated in neurodevelopmental disorders8, 36-38. For each dataset, we extracted unique 
genes from the CNV regions reported and aligned these NDD CNV gene lists with the genes 
for which MAE/BAE status could be inferred from LCLs and from fetal brain (above).
NDD GWAS/SNV datasets
In order to test the hypothesis that variants likely to act via gene expression would show 
underrepresentation compared to variants likely to act via gain-of-function mechanisms, we 
examined data from several recent neuropsychiatric disease studies. First, we utilized the 
supplementary data provided by a schizophrenia genome-wide association study including 
annotation of associated SNPs (threshold P < 5 × 10−8)39. In brief, the relevant annotations 
were 1) genes in credible regions of an associated SNP (protein-coding genes based on 
GENCODE with 20 kb flanking region on each side or where there is no intersecting gene, 
the nearest gene within 500 kb), 2) blood eQTLs in Wright et al 40 with a transcript within 
1Mb and PeQTL<1×10−4 ; 3) brain eQTLs (meta-analysis of GSE8919, GSE15745, 
GSE30272, GSE1522241-44) with a transcript within 1Mb and PeQTL<1×10−4, and 4) 
missense variants within the credible regions.
Next, we used supplementary data from two exome sequencing studies of SNVs for ASDs. 
Unfortunately, although missense mutations can act via gain-of-function or loss of function, 
there are no validated methodologies to predict without onerous experimentation. Thus we 
used several approaches to enrich our data under the assumption that genes acting via loss-
of-function would show some enrichment for frameshift, nonsense, or splice site mutations 
(likely to result in no expression of an allele) and genes acting exclusively via gain-of-
function would show only missense mutations but no enrichment for frameshift, nonsense, 
or splice site mutation in affected individuals. The first study provided an integrated analysis 
of de novo, inherited and case-control loss-of-function variant counts, as well as de novo 
missense variants predicted to be damaging with q < 0.3 by TADA (transmission and de 
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novo association), based on examination of over 3,800 cases and 9,900 controls 45. We 
defined likely loss-of-function genes as those showing a de novo loss-of-function mutation 
(LoF: frameshift, nonsense, donor/acceptor splice site mutations) in at least one case and no 
LoF mutations in controls. We defined potential gain-of-function genes as those showing no 
LoF de novo mutations in cases with association signal thus coming primarily from 
missense (probably damaging, as defined by PolyPhen-245) variants. (Note that the 
‘probably damaging’ category in PolyPhen-2 does not refer specifically to loss of function, 
but only to the likelihood of altered function.) The second study only included de novo 
SNVs identified in 2,500 simplex families comparing cases and sibling controls47. We 
defined likely loss-of-function genes as those with de novo likely gene disrupting mutations 
(LGD: frameshift, nonsense, and splice site) in at least one case and none in control siblings 
and potential gain-of-function genes as those with at least two de novo missense mutations 
in cases and none in siblings and no de novo LGD mutations in cases. We tested the full 
gene list examined compared to the genome-wide LCL and fetal brain MAE/BAE genes and 
found no difference in representation, showing that exome sequencing adequately covered 
the genome. In order to identify genes likely to act in a recessive manner on autism, we 
utilized a previous dataset of genes with either rare homozygous or compound heterozygous 
nonsense or splice site (LoF) mutations in autism cases, but not in controls, provided in a 
supplementary table48.
Haploinsufficiency, constraint, and OMIM datasets
In order to support our hypotheses about haploinsufficiency and gain-of-function, we 
utilized several published or public datasets. A previous publication included a 
supplementary table providing their predictions of haploinsufficient (HI) and haplosufficient 
(HS) genes49. We used predictions of at least 0.9 to indicate likely HI status and not more 
than 0.1 to indicate likely HS status. A recent study derived constraint scores in order to 
interpret pathogenicity of de novo mutations50. We downloaded a table of Z-scores for 
constraint including synonymous, missense, and loss-of-function mutations (http://
atgu.mgh.harvard.edu/webtools/gene-lookup/lookupGene; downloaded 1/05/15). In order to 
predict gain-of-function, we calculated the difference between constraint Z-scores for 
missense and loss-of-function mutations and considered the top 10% of genes, under the 
assumption that genes more constrained for missense than loss-of-function mutations are 
most likely to act via gain-of-function. In order to identify human disease genes primarily 
acting via gain-of-function, we searched the Online Mendelian Inheritance in Man (OMIM) 
database (http://www.ncbi.nlm.nih.gov/omim). We used search terms ‘lossoffunction’ and 
‘gainoffunction’ and retained unique genes annotated with only gain-of-function.
Statistical analysis
ANOVA test and Tukey's ‘Honest Significant Difference’ method was used to assess the 
differences in expression level between groups of different/same state genes in the analysis 
of expression change between two clonal cell lines. To confirm differences in MAE and 
BAE gene variance in the GTEx data, we used Wilcoxon test. To assess differential 
representation of MAE and BAE genes in evQTL targets and disease datasets, we used the 
chi-square test (or a one-sided Fisher exact test when expected counts were <5 for any cell). 
Meta-analysis of the 7 NDD CNV studies was performed using the Mantel-Haenszel method 
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as implemented in the R package (Meta, v 4.0). The two-tailed test of population proportion 
(z-test) was used to assess the difference in high-variance versus low-variance genes in 
evolutionary comparisons. A chi-square test was used to assess differences in MAE/BAE 
distribution across the three evolutionary model categories (directional, expression-
constrained, and relaxed).
RESULTS
Inference of MAE genes in fetal brain
Our classification analysis of existing chromatin data from fetal brain dataset predicted 4690 
genes as MAE and 7408 as BAE with rank of 50% or higher in expression. The relatively 
high number of genes with this expression rank (>12,000) is likely due to fact that the 
transcriptome is generally very broad in this developing tissue (76% of assayed genes)51. 
This, and the fact that moderate to low expression genes are more likely to be MAE, may 
contribute to the different estimates of MAE proportion in LCLs and fetal brain (0.13 vs. 
0.39). However, it is also possible that the discrepancy is partially due to the fact that 
expression in this dataset was measured by microarray, which is more sensitive than RNA-
seq for lower-expressed genes. The predictions are very significantly enriched with 
monoallelic genes from an existing human neuronal dataset of experimentally measured 
monoallelic expression27. While the study had an idiosyncratically low level of confirmed 
MAE as a whole (<2%), out of the 145 genes positively identified as MAE, 107, or 74% 
were predicted MAE by our classifier. The expected baseline rate in our dataset was 39% (P 
< 2.2 × 10−16). Further examination revealed that confirmed MAE genes from the Jeffries 
study were uniformly distributed within the predicted region based on the chromatin data, 
suggesting that the overall very low calling rate, rather than biological differences is likely to 
be responsible for the relatively small overlap of predicted and confirmed genes (Figure S1).
For a deeper validation of our predictions, we used experimental data from two independent 
approaches: we compared our predictions to published RNA-FISH in mouse fetal brain, and 
to genome-wide allele-specific RNA-Seq in multiple mouse clonal neuronal progenitor cells 
(NPCs). It shows that our chromatin inference is as accurate as experimentally-determined 
MAE status (Figure 1).
Both of these datasets show a good agreement between the genes’ MAE status as inferred 
from the chromatin signature in human fetal brain and the MAE status of the orthologous 
mouse genes experimentally determined in mouse fetal brain and NPC clones. Considering 
the overall significant conservation of MAE status between human and mouse, this analysis 
provides stronger evidence than any plausible experiment using human samples.
Relationship between monoallelic transcription and mRNA level
Level of mRNA is the main output of the cell’s transcription regulatory machinery. We have 
previously observed that the specific allelic state in an MAE gene between clonal cell 
lineages can have significant consequences for the transcript levels: for example, clones of 
human lymphoblastoid cells expressing a single allele of APP gene showed lower transcript 
level than clones with both alleles expressed equally, as measured by real-time PCR7. 
Savova et al. Page 8
Mol Psychiatry. Author manuscript; available in PMC 2017 November 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
However, these observations were limited to a small number of genes. RNA-Seq analysis of 
mRNA from similar clones2 provided means to assess whether this quantitative relationship 
holds genome-wide.
We analyzed a total of 42 genes with different status (monoallelic and biallelic) in two 
clones (DF1 and DF2) derived from the same human LCL (GM12878), and 617 genes with 
consistent monoallelic or biallelic status in both clonal lines. We found that genes with 
consistent biallelic or monoallelic status showed less expression level difference than genes 
with different status (P < 0.01; Figure 2a). Further, for genes with different status, expression 
in the monoallelic state was lower overall (P <1.1 × 10−16; Figure 2b, Table S3). The effect 
was more pronounced in one direction, which was likely to be due to difference in coverage 
in the two sequencing libraries (higher coverage in the DF1 library is likely to lead to fewer 
false detections of allelic bias), and to lower average difference in bias between the mono- 
and biallelic state in the direction exhibiting less pronounced effect (0.21 versus 0.25). In 
contrast, having the same status (both monoallelic versus both biallelic) was not associated 
with any difference in expression level (P < 0.95).
Genes with MAE status show higher inter-individual expression variability in humans
Previous studies of clone-specific phenomena, such as X-inactivation, have shown that 
developmental processes lead to variability in clonal composition 5. Since MAE genes are 
more variable in their expression level across clones, we hypothesized that they would also 
make a greater contribution to expression variability across individuals than BAE genes. To 
test this prediction, we took advantage of a large-scale publicly available gene expression 
RNA-seq dataset measuring expression in multiple primary human tissues – GTEx 48. We 
predicted gene status as MAE and BAE using specific chromatin signature, as previously 
described2. As the source of chromatin data, we used the closest available cell type: to 
analyze GTEx expression data from 393 whole blood samples, genes were classified as 
MAE or BAE using chromatin data obtained in GM12878 lymphoblasts by the ENCODE 
project52. For the brain, 108 GTEx samples of human cortex were used, and genes were 
classified as MAE or BAE using ChIP-Seq data obtained from human fetal brain samples in 
the Epigenome Roadmap19. Standard deviation was consistently and significantly higher in 
all tested tissues for MAE genes compared to BAE genes, for all bins (Figure 3a and Table 
S2, Table S3). We thus conclude that expression variation between individuals is 
significantly higher for MAE compared with BAE genes.
Targets of evQTLs are enriched for MAE genes
Next, we hypothesized that if MAE-associated expression variation is functionally important 
within the human population, genes undergoing MAE would also be subject to germline 
polymorphism associated with expression variance. We thus analyzed data on expression 
variance quantitative trait loci (evQTLs) in human LCLs to determine whether genes with 
major evQTLs are also more likely to be MAE in LCLs24. We performed analyses using 
data based on chromatin signature in LCLs, extensively validated using allele-specific RNA-
Seq in clonal LCLs2. However, we also wanted to assess any brain-specific effects using the 
classification described above (also see Methods and Table S1). Of the 166 genes with 
reported cis evQTLs, 49 were found in our dataset with MAE/BAE status in LCLs and 104 
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were found with MAE/BAE status in fetal brain. Compared with the expected proportion of 
0.13 in the LCL dataset, we found 18 (0.36) evQTL targets to be MAE compared with 31 
BAE (P < 1.1 × 10−6). Compared with the expected proportion of 0.39 in the fetal brain 
dataset, we found 73 (0.7) evQTL targets to be fetal brain MAE compared with 31 BAE (P < 
7.8 × 10−11; Figure 3b). In order to rule out the possibility that eQTLs targeting MAE genes 
would appear to be evQTLs, we assessed eQTLs in this dataset25. A small number of evQTL 
target genes also showed a significant eQTL (2 MAE and 6 BAE), and our results remain 
unchanged excluding these eQTL targets.
The analysis above may be subject to confounding factors, specifically expression level. For 
example, highly expressed genes (like housekeeping genes) show low variation between 
individuals. The same genes tend also to be BAE. This will generate an association between 
variation in gene expression, evQTLs and MAE. To address this possibility, we performed a 
regression analysis with expression level in GM12878 as a nuisance variable. MAE/BAE 
status was shown to be the significant predictor of the presence of evQTL in the gene (P < 
1.6 × 10−5) but the effect of expression level wasn't significant (P < 0.6).
Genes with MAE status are overrepresented in inter-species variance and directional 
expression level selection and underrepresented in expression-constrained genes
Standing variation under little constraint in a population can provide a substrate for 
directional selection; thus we hypothesized that if MAE genes have greater expression 
variance within a population, they might also show increased directional selection during 
evolution. To assess whether MAE gene expression variability might play a role in inter-
species differences, we examined data from a recent publication describing human-
chimpanzee differences in gene expression at the RNA and protein level in LCLs26. 
Supplementary data provided with this publication included 3,390 LCL expressed genes, of 
which 3,230 (72 MAE, 3,158 BAE) intersected with genes meeting our criteria of length > 
2,500 and expression level above 50th percentile in LCLs. To compare the inter-species 
expression level change for MAE genes to BAE genes, we examined the proportion of MAE 
genes in high and low variance genes, as defined by the original publication26. Genes with 
MAE status were marginally overrepresented in high variance genes (RNA P < 0.04 two-
sided; protein P < 0.082, one-sided). The weak significance values were largely due to the 
relatively small proportion of genes inferred to be MAE in LCLs in the overall dataset (2% 
of the protein and 1.3% of the RNA dataset). We found that these results were more robust 
for fetal brain predictions, where more MAE genes were assayed (14% of such genes, RNA 
P < 2 × 10−14; Protein P < 7 × 10−9), despite LCL expression data.
Next, we examined the distribution of models to which BAE and MAE fit best, combining 
human and chimpanzee lineage selection into three categories: 1) directional selection along 
human or chimpanzee lineage, 2) no mean expression difference, indicative of constraint, 3) 
relaxation of constraint along human or chimpanzee lineage26. We found an overall 
difference in the RNA model assignments of LCL and fetal brain MAE and BAE genes (P < 
0.05). Specifically, MAE genes are overrepresented in directional selection for human and 
chimpanzee lineages and underrepresented in genes with no mean LCL expression 
difference (Figure 4). The same pattern held true for fetal brain prediction and LCL protein 
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expression (Table S4). Although intuitively, we might expect within-species variance to 
differ across these selection categories, we found that for BAE genes, average variance 
increased approximately 10% from relaxed (0.00050) to directional (0.00055) to equal-
expression (0.00059). For MAE genes, average variance increased approximately 2-fold 
between these same categories (0.0013 to 0.0024 to 0.0048). Within each category, variance 
for MAE genes was higher than for BAE genes (each Pone-sided < 0.05). In the Khan et al26 
paper from which these data were derived, a conclusion reached was that variation was 
buffered for protein compared to RNA expression. In contrast, we found differences between 
BAE and MAE genes to be consistent between RNA and protein expression (above).
Genes with MAE status are underrepresented in pathogenic CNVs, but not in polymorphic 
CNVs
Given that MAE genes were found to vary in expression level more than BAE genes, and 
given that those differences seem to have functional significance in humans, we asked how 
MAE genes might intersect with genomic variation influencing gene expression. A previous 
study assessed distribution of 212 genes that were identified as MAE by allele-specific 
expression analysis in patient-derived clonal neuronal progenitor cells53. It reported 
overrepresentation of those MAE genes in known pathogenic CNVs from multiple datasets. 
We used our much larger gene set to assess enrichment of MAE genes in the same 
neuropsychiatric datasets8, 28-35, 38, as well as several additional neuropsychiatric CNV 
datasets36, 37, 54, 55. The overall rate of fetal brain MAE is 0.39. In the set of control CNVs, 
the proportion is 0.37 (P < 0.21). Unlike the aforementioned study27, we found that each of 
the NDD datasets showed decreased proportions of MAE genes (0.26-0.37 with 
DerSimonian-Laird estimator of heterogeneity tau^2= 0 across NDD datasets; P < 2.2 × 
10−10 Mantel-Haenszel meta-analysis compared with fetal-brain expressed, and P < 0.02 
compared with control CNVs from dbVAR, Figure 5a). We further validated the result with a 
higher expression level cutoff (P < 0.003, Table S5).
Genes with MAE status are depleted in predicted haploinsufficient gene sets
To further test our model that MAE variants are unlikely to act via haploinsufficiency, we 
utilized a recent study predicting haploinsufficient genes in the human genome49. We 
compared genes with probability of haploinsufficiency (HI) greater or equal to 0.9 to genes 
with HI less than or equal to 0.1 [strongly predicted to be haplosufficient (HS)] out of all 
genes scored. As our model predicts, genes likely to be HI show reduced proportion of fetal 
brain genes with MAE signature (0.28; P < 3.6 × 10−6), and further, genes likely to be HS 
show increased proportion of fetal brain genes with MAE signature (0.4; P < 0.052) (Figure 
5b, 5c).
Disease risk nucleotides acting on gene expression (eQTLs) are dramatically depleted of 
MAE genes
In order to examine an independent set of neuropsychiatric risk genes not derived from 
CNVs, we analyzed data from schizophrenia genome-wide association meta-analysis39. 
Within the full list of 347 unique genes potentially implicated across 108 schizophrenia loci, 
we found only a modest and non-significant decrease in brain MAE genes (0.35) in the 
complete dataset. However, this study also provided a filtered subset, based on an overlap 
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between risk loci and eQTLs in both blood and brain, as these are more likely to be 
functionally significant variants (via expression level). In genes having a blood eQTL, 
inferred brain MAE genes were dramatically depleted (0.20, P < 1.7 × 10−4). In reported 
brain eQTLs, inferred brain MAE genes were found at only a small fraction (0.09, P < 
0.0056) (Figure 5b).
However, based on the functional importance implied by directional selection in humans, we 
hypothesized that representation of MAE genes would vary based on the predicted role of 
the variant allele. Although both CNVs and eQTLs are likely to act via expression level 
changes, protein coding mutations can act via additional mechanisms, such as gain-of-
function. There were a small number of common protein coding missense variants in the 
same set of potentially implicated genes in schizophrenia association regions (N=11), and 
brain MAE genes appear to be strongly overrepresented in these protein-altering candidates 
(0.75, P < 0.042, one-sided; Figure 5c). We therefore wanted to more specifically examine 
our prediction that genetic variation in MAE genes acting via loss-of-function and via gain-
of-function would show opposite patterns.
Autism genes enriched for loss-of-function single nucleotide variants compared to autism 
genes enriched only for missense variants suggest a novel hypothesis
To examine rare single nucleotide variants (SNVs), we analyzed data from two recent autism 
spectrum disorder (ASD) exome sequencing studies45, 47. The first provides an analysis of 
both de novo and inherited rare exome variants in >3,800 case and >9,900 control subjects, 
identifying ASD-associated genes with FDR q-values < 0.3. ASD associated genes were 
suggestively depleted overall in fetal brain MAE genes (0.29, P < 0.07). From these 
probable ASD risk genes, we examined genes with de novo loss-of-function (LoF) mutations 
(equivalent to deletion CNV) in cases but not controls, and we found brain MAE genes 
similarly (but non-significantly) underrepresented (0.2, P < 0.025; Figure 5b). However, 
ASD-associated genes driven by missense variants (with no observed proband de novo LoF 
mutations) showed (non-significant) overrepresentation of genes with MAE chromatin 
signature in brain (0.43, P < 0.48; Figure 5c). The second study examined only de novo 
variants in >2,500 ASD simplex cases and sibling controls. When we restricted to genes 
with at least 1 de novo LoF mutation in cases and no LoF de novo mutations in controls, we 
similarly see an underrepresentation of MAE genes (0.33, P < 0.069; Figure 5b). However, 
when we examine genes with at least 2 de novo proband missense mutations with no de 
novo LoF proband mutations and no sibling missense mutations observed, we see 
overrepresentation of MAE genes (0.46, P < 0.24; Figure 5c). Although missense variants 
can act via either gain-of-function (GoF) or LoF mechanisms, we enriched the missense 
categories examined here for GoF by excluding genes showing any evidence of likely LoF 
(e.g. frameshift, nonsense) de novo variants in affected probands. Although none of these 
observations are statistically convincing on their own, together these data suggest a 
hypothesis that MAE genes may be more likely to act via GoF (i.e. protein function is 
important but reducing amount 0.5X does not lead to disease), while BAE genes may be 
more likely to act via LoF (inactivating one of two copies leads to disease).
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Genes more constrained for missense than for LoF mutation are enriched for inferred MAE 
status
In order to test our hypothesis utilizing an independently-defined set of genes likely to act 
via GoF, we utilized a study providing constraint scores for genes across the genome50. 
Constraint was estimated separately for missense and for LoF mutations (http://
atgu.mgh.harvard.edu/webtools/gene-lookup/lookupGene), and we infer that genes showing 
higher levels of constraint for missense mutations than for LoF mutations are most likely to 
act via GoF. We thus compared MAE ratio for the top 10% of genes showing higher 
constraint for missense mutations than for loss-of-function mutations compared with all 
genes scored. We find a higher proportion of brain MAE genes (0.45; P < 3.7 × 10−4) among 
this missense-constrained gene set. To further support the hypothesis that MAE genes are 
likely to be pathogenic via GoF, a search of OMIM using the term ‘gain-of-function’ and 
excluding the term ‘loss-of-function’ shows an increased proportion of fetal brain predicted 
MAE genes in the group annotated only with ‘gain-of-function’ (0.55, P < 7.8 × 10−5).
Genes with predicted MAE status are enriched among recessive autism genes
Another class of genes involved in disease, but likely to be haplosufficient, are those acting 
via a recessive model. Although recessive mutations are likely to act via LoF, the recessive 
model requires both alleles to be affected, with no fully functional allele remaining, so are 
unlikely to be highly dosage sensitive. We tested our prediction that genes likely to act 
recessively on autism would also be more likely to be in the MAE class utilizing recently 
published data48. Autosomal genes with either homozygous or compound heterozygous 
loss-of-function SNVs (nonsense or splice site) have increased likelihood to be classified as 
MAE in fetal brain (0.69, P < 9.5 × 10−4).
Meta-analyses
In order to confirm the overall pattern of eQTL/LoF/HI underrepresentation and GoF/HS/
recessive overrepresentation of fetal brain MAE genes relevant to neurodevelopmental 
disorders, we performed a meta-analysis across the schizophrenia GWAS, autism exome, 
constraint and HI/HS prediction, and OMIM categories. Overall, fetal brain MAE genes are 
underrepresented in predicted pathogenic genes likely to affect expression level or be 
haploinsufficient (P < 7.5 × 10−11) (Figure 5b). In contrast, fetal brain MAE genes are 
overrepresented in predicted pathogenic genes likely to incur gain of function or be 
haplosufficient (P < 1.4 × 10−6) (Figure 5c).
DISCUSSION
In light of recent data indicating that somatic MAE affects a large proportion of expressed 
genes in multiple tissues, we asked how potential differences in expression level between 
monoallelic and biallelic cells affect variation in the population, and what the implications 
for evolution and disease would be. Our focus was on two tissue types: blood as the best 
studied MAE system in human, and brain as a system with particular sensitivity to small 
regulatory effects. We used a published and validated chromatin signature method to infer 
monoallelic expression in human fetal brain and found that the results of the method are in 
agreement with experimentally measured monoallelic expression in NPCs. The application 
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of this method to the neural lineage has already been validated in mouse 3. Notably, for 
analyses where we were able to utilize both LCL and fetal brain data, results were 
consistent, suggesting that large-scale patterns for this class of genes are evident across 
tissues, much as has been found for genetic regulation of gene expression21. However, 
because of technical differences, direct comparisons cannot be made between MAE 
predictions in LCLs and fetal brain.
We first experimentally determined that the monoallelic state shows lower expression than 
the biallelic state for the same gene in human cells by performing a meticulous technical 
analysis of genome-wide RNA-seq data from two LCL clonal cell lines and comparing 
expression of the same gene across tissues with MAE compared with BAE status. Similar 
results have been reported previously for mouse NPCs6. One methodological difficulty in 
extending the analyses performed on mouse NPCs to human data is that in previous studies 
the biallelic state was defined merely as the absence of confirmed monoallelic state, 
establishing low coverage as a potentially significant source of noise. This is particularly 
concerning in human data where only few diagnostic loci are available to distinguish 
between the two alleles. We therefore improved on the existing methodology by utilizing 
separate statistical tests to positively predict both biallelic and monoallelic expression for 
our comparisons.
We then showed that MAE genes have higher variance than BAE genes in humans, by taking 
advantage of a large dataset encompassing transcriptome-wide measurement of multiple 
tissues derived from dozens of individuals. Given that MAE genes differ in expression level 
across clones, this variability is likely to be due, at least in part, to clonal composition 
differences during development. Interestingly, these observations suggest that expression 
variation is tolerated for MAE genes, from individual cells to the whole organism. However, 
the question remained whether this variation has functional consequences.
We hypothesized that if high levels of expression variance are tolerated, or even adaptive, 
variance might be maintained in the population through genetically-encoded regulation, such 
as evQTLs. Thus, we examined human targets of regulation in expression variance, and 
found that indeed genes with MAE status are also more frequently the target of genetic 
regulation of expression variance in humans. Further experimentation would be necessary to 
determine whether these genetic cis evQTLs act on expression variance via MAE or through 
an independent mechanism.
We further conjectured that variance in expression level of MAE genes could provide 
substrate for evolutionary selection if these genes are functionally significant. If so, MAE 
genes would be more likely to show cross-species differences in expression level and 
evidence for directional selection compared with BAE genes. We analyzed data on human-
chimpanzee gene expression at the RNA and protein level. We found support for our 
hypothesis that MAE genes would show greater inter-species variance in expression than 
BAE genes. In addition, MAE genes more often fit a model of directional selection in either 
species and less often showed similar expression level in humans and chimpanzees than 
BAE genes. Together, these data suggest that MAE increases variation in gene expression 
level, which provides a substrate for evolutionary change. Genes undergoing MAE might be 
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particularly likely to differentiate humans from non-human primates, as evidenced from an 
underrepresentation of genes with similar expression levels. These data also support our 
model that MAE expression variance is not only tolerated, but also adaptive, and is 
consistent with our recent finding that at the nucleotide level, MAE genes show increased 
diversity and evidence for balancing selection compared with BAE genes56.
Finally, we wanted to assess whether MAE status is predictive of pathogenic effects 
associated with expression level changes. Copy number variants, or deletions/duplications 
>1kb, have been shown to affect expression level of genes contained within them, and be 
major risk factors for neurodevelopmental and neuropsychiatric disease, such as autism and 
schizophrenia. Thus our model would predict that MAE genes can tolerate expression 
changes and would be non-pathogenic if contained in a CNV. Indeed, analysis of the large 
dataset of MAE genes we predicted in fetal brain provides strong evidence that these genes 
are underrepresented in pathogenic CNVs compared to polymorphic CNVs or all expressed 
genes. A previous study reached an opposite conclusion27. Notably, that study assessed a 
small fraction (<2%) of the number of MAE genes analyzed here. More importantly, the 
overall proportion of MAE genes in the CNV datasets was calculated without taking into 
account that only a fraction of the genes in those datasets were classified as MAE or BAE. 
When the same data were re-analyzed correcting for the number of genes positively 
identified as MAE or BAE, there was no significant over- or under-representation of MAE 
genes in that study among neurodevelopmental CNVs (Table S6).
Our CNV results are supported by analysis of eQTLs overlapping schizophrenia risk loci 
and loss-of-function exome variants in autism, within which genes with MAE chromatin 
signature are also dramatically depleted. Both CNVs and loss-of-function variants are likely 
to act via haploinsufficiency. In contrast, genes with schizophrenia missense polymorphisms 
and autism missense or recessive variants are overrepresented in MAE genes. Missense 
variants may act through gain-of-function mechanisms (functional properties not amount of 
protein lead to disease), hence although MAE genes can be functionally important (and 
pathogenic), this seems to be mediated either by specific protein sequence changes which 
may incur gain-of-function or by complete knock-out.
Thus, our observations might be generally useful in interpreting genetic variation in the 
context of human disease. A recent study of stochastic monoallelic expression suggests that 
it could contribute to variance around predicted genotype-phenotype relationships such as 
penetrance, expressivity, and discordant monozygotic twins53. We further propose that 
specific genotype-phenotype relationships might be more accurately predicted in the 
population with knowledge of their (predicted) MAE status. SNVs in genome or exome 
sequencing results without convincing data available in research or clinical databases can be 
difficult to interpret. Current strategies include prediction of how disruptive an amino acid 
substitution is likely to be (e.g. PolyPhen), evolutionary conservation or overall constraint as 
an indicator of functional importance, and tissue-specific expression. We propose that 
known tissue-specific MAE status could be used as an additional prediction tool, for 
example gain-of-function or recessive changes in genes of the MAE class might be more 
likely to be pathogenic, and heterozygous loss-of-function changes in MAE genes, less 
likely to be pathogenic.
Savova et al. Page 15
Mol Psychiatry. Author manuscript; available in PMC 2017 November 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In conclusion, we have used a variety of data to support the hypothesis that MAE is an 
important epigenetic regulatory mechanism influencing expression level variance both 
within the population and across species. This carries implications for a critical role for 
MAE in evolution, maintenance of variation in the population, and with future follow-up 
could prove valuable to prediction of pathogenicity in neurodevelopmental disorders.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Experimental confirmation of fetal brain MAE status in mouse neural cell lines and 
tissue
(A) Six mouse orthologues confirmed MAE by RNA-FISH in mouse brain 6. Each circle 
represents a gene, colored by status (MAE=blue, BAE=orange). Expected fraction of MAE 
under the null hypothesis based on our prediction dataset (0.39) is indicated in the vertical 
bar graph. Orthologous genes were defined using OrthoDB database 57.
(B) MAE gene status in experimental RNA-seq data on mouse neuronal progenitor clonal 
cell lines 6. MAE status was determined as previously described 2. Fraction of measured 
MAE genes (blue) and BAE genes (orange) among predicted BAE (left) and MAE (right) 
orthologues. Expected fraction of MAE under the alternative hypothesis of human-mouse 
differences but not predicted-experimental or NPC-brain differences contributing based on 
empirical data comparing mouse and human experiments from the same tissue 58 is shown in 
the vertical bar graph.
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Figure 2. Expression differences in MAE genes between two clones
Expression differences are shown according to monoallelic state in each clone as measured 
in DESeq-“normalized counts” and approximately equivalent to log2 fold-change 59.
(A) Absolute difference in expression levels for “consistently biallelic” genes – genes with 
biallelic status in both clones, and for “mono → biallelic” genes – genes with monoallelic 
status in one clone and biallelic status in the other clone.
(B) Difference in expression levels between clone DF1 and clone DF2 for four groups of 
genes defined by allelic expression: “consistently biallelic”, as in A; “consistently 
monoallelic” – genes with monoallelic status in both clones; “mono in DF1, bi in DF2” – 
genes with monoallelic status in DF1 and biallelic status in DF2; “mono in DF2, bi in DF1” 
– genes with monoallelic status in DF2 and biallelic status in DF1. Mean bias difference 
(MBD) between DF1 and DF2 is shown for each of the groups below.
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Figure 3. Genes with MAE status show elevated expression level variation and are 
overrepresented among genes targeted by evQTL variants across tissues
(A) LCL: lymphoblastic cell lines; Blood: whole peripheral blood samples; Brain: brain 
cortex samples 48. MAE: genes predicted to be MAE in the tissue by chromatin signature. 
BAE: genes predicted to be BAE in the tissue by chromatin signature. Shown are standard 
deviations for MAE and BAE classified genes. See also Table S2.
(B) Left: proportion of MAE and BAE genes as predicted by chromatin signature in fetal 
brain genome-wide (genome), and among genes targeted by evQTLs (dataset from Hulse 
and Cai)24; right: same for predicted MAE and BAE genes in LCLs.
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Figure 4. Genes with inferred MAE status are more often subject to directional selection on 
expression level between human and chimpanzee
Proportion of genes identified as subject to conservational constraint (grey), directional (red) 
and relaxed (green) selection in RNA and protein expression levels in blood 26. LCL: genes 
predicted MAE by chromatin signature in LCLs. BRAIN: genes predicted MAE by 
chromatin signature in fetal brain.
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Figure 5. Mechanism of gene pathogenicity is associated with MAE status
(A) Proportion of MAE genes in CNV datasets representing controls (dbVar, red square) and 
pathogenic neurodevelopmental CNVs (individual datasets: blue squares, meta-analysis: 
blue diamond) compared with the genomewide proportion (red diamond). Proportion is 
calculated as percent of unique genes contained in a CNV with MAE status based on all 
genes with either status assigned. SCZ, schizophrenia: CNVs associated with schizophrenia. 
95% confidence intervals for each estimate are shown with horizontal bars. The red vertical 
line represents the proportion of all genes, and the dotted blue line represents the estimated 
proportion in neurodevelopmental CNVs estimated by meta-analysis. Studies analyzed: 
Cooper et al 31, Stefansson et al [a] 37, Stefansson et al [b] 29, Mowry and Grattan 28, 
Murdoch and State 30, Rosenfeld et al 36, Coe et al 54, Olson et al 55.
(B) Proportion of MAE genes in datasets representing haploinsufficient, expression-altering, 
and loss-of-function pathogenic genes (individual datasets: blue squares, meta-analysis: blue 
diamond) compared with the genomewide proportion (red diamond). Proportion is 
calculated as percent of unique genes in a dataset with MAE status based on all genes with 
either status predicted. HI, haploinsufficient: genes with haploinsufficiency scores at or 
above 0.9. SCZ, schizophrenia PGC meta-analysis: annotated genes in credible regions of 
SNP association 36. eQTL, expression quantitative trait locus: defined as in the study 36. 
LoF, loss-of-function: genes with de novo frameshift, nonsense, splice mutations in at least 
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one autism case and no controls. 95% confidence intervals for each estimate are shown with 
horizontal bars. The red vertical line represents the proportion of all genes, and the dotted 
blue line represents the estimated proportion in pathogenic genes estimated by meta-
analysis. Studies analyzed: brain and blood eQTLs 39; DeRubeis et al 45, Iossifov et al 47, 
Huang et al 49.
(C) Proportion of MAE genes in datasets representing recessive, missense, and gain-of-
function pathogenic genes and haplosufficient genes (individual datasets: blue squares, 
meta-analysis: blue diamond) compared with the genomewide proportion (red diamond). 
Proportion is calculated as percent of unique genes in a dataset with MAE status based on all 
genes with either MAE or BAE status predicted. HS, haplosufficient: genes with 
haploinsufficiency scores at or below 0.1. Missense: genes with no de novo LoF mutations 
in autism cases and either q<0.3 or at least two de novo missense mutations in cases and no 
missense mutations in controls. Constrained: genes in the top 10% showing higher constraint 
for missense variants than loss-of-function variants. 95% confidence intervals for each 
estimate are shown with horizontal bars. The red vertical line represents the proportion of all 
genes, and the dotted blue line represents the estimated proportion in pathogenic genes 
estimated by meta-analysis. Studies analyzed: same as in panel B, and also Samocha et al 50, 
Lim et al 48.
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